MK 8351Alternative Names: MK-8351
Latest Information Update: 22 Aug 2013
At a glance
- Originator Merck & Co
- Class Antiasthmatics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 16 Aug 2013 Preclinical trials in Asthma in United Kingdom (Inhalation)
- 16 Aug 2013 Merck plans a phase I trial for Asthma in the UK (NCT01926002)